NCT02624596

Understanding How Ketamine Brings About Rapid Improvement in OCD

NMDAR Modulation As a Therapeutic Target and Probe of Neural Dysfunction in OCD

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to understand how ketamine brings about rapid improvement in Obsessive-Compulsive Disorder (OCD) symptoms.

Detailed description

Obsessive-Compulsive Disorder (OCD) is a chronic and disabling disorder that costs the economy over $2 billion annually and represents a significant public health problem. This study aims to build on our discovery that a potent NMDA receptor antagonist, ketamine, has rapid (in hours) and robust therapeutic effects in OCD. The proposed projects test the acute mechanism of action of ketamine at the level of molecules, circuits, and network synchrony to determine how NMDA receptor antagonism modifies the underlying pathology of OCD to relieve repetitive thoughts and behaviors.

Conditions

• Obsessive-Compulsive Disorder

Interventions

Type	Name	Description
DRUG	Ketamine	OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
DRUG	Midazolam	OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion

Timeline

• Start date: 2016-06-01
• Primary completion: 2026-06-01
• Completion: 2026-06-01
• First posted: 2015-12-08
• Last updated: 2025-05-31

Locations

1 site across 1 country: United States